STOCK TITAN
  1. Home
  2. News
  3. AMAM

Ambrx Biopharma Inc. - AMAM STOCK NEWS

Welcome to our dedicated news page for Ambrx Biopharma (Ticker: AMAM), a resource for investors and traders seeking the latest updates and insights on Ambrx Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ambrx Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ambrx Biopharma's position in the market.

News
Ambrx Shareholders Approve Acquisition by Johnson & Johnson
Rhea-AI Summary
Ambrx Biopharma, Inc. shareholders approved a merger agreement with Johnson & Johnson, with shareholders set to receive $28.00 per share in cash. The CEO highlighted the company's focus on protein engineering innovation and promising pipeline for cancer treatments. Over 99% of votes were in favor of the merger, signaling strong shareholder support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
acquisition
-
News
Ambrx Announces Sale to Johnson & Johnson
Rhea-AI Summary
Ambrx Biopharma, Inc. (AMAM) has entered into a definitive agreement with Johnson & Johnson for acquisition at $28.00 per share in cash, representing an approximately 105% premium to Ambrx’s closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion. The acquisition aims to advance scientific research to treat cancers with high unmet needs. Ambrx's proprietary Antibody Drug Conjugate (ADC) technology and leading prostate cancer candidate are key highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
101.54%
Tags
none
-
News
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
Rhea-AI Summary
Johnson & Johnson (JNJ) strengthens its commitment to oncology innovation by acquiring Ambrx Biopharma, Inc. (AMAM) in an all-cash merger transaction for approximately $2.0 billion. Ambrx's clinical and preclinical programs, including lead product candidate ARX517, a prostate-specific membrane antigen (PSMA)-targeting antibody drug conjugate (ADC), align with J&J's goal of developing next-generation ADCs and targeted oncologic therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
101.54%
Tags
acquisition
News
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
Rhea-AI Summary
Ambrx Biopharma, Inc. (AMAM) will be added to the NASDAQ Biotechnology Index (NBI), effective December 18, 2023. This follows a transformational year for Ambrx, including voluntarily transferring to Nasdaq from the New York Stock Exchange, changing parent company domicile to Delaware, and terminating the ADS program. CEO Daniel J. O’Connor believes these changes may enhance long-term shareholder value and increase the company's profile in the investment community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
News
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
Rhea-AI Summary
Ambrx Biopharma, Inc. (AMAM) announced positive clinical results for its anti-PSMA antibody drug conjugate ARX517 in the APEX-01 trial for metastatic castration-resistant prostate cancer. Cohort 9 showed no dose limiting toxicities or serious adverse events, with two patients experiencing rapid PSA reduction after one dose. Cohort 8 is fully enrolled, and the recommended phase 2 dose is expected by early next year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
clinical trial
-
News
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments
Rhea-AI Summary
Ambrx Biopharma announces positive results from Phase 1 portion of APEX-01 trial for ARX517 in metastatic castration-resistant prostate cancer (mCRPC)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
News
Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023
Rhea-AI Summary
Ambrx Biopharma Inc. will host an in-person key opinion leader event during the ESMO Congress 2023, featuring preliminary data from APEX-01 study on ARX517 in prostate cancer patients. Virtual webcast and presentation materials will be available for those unable to attend.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
conferences
-
News
Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Summary
Ambrx CEO participates in fireside chat and one-on-one meetings at Cantor Fitzgerald Global Healthcare conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.22%
Tags
conferences
-
News
Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Conferences
Rhea-AI Summary
Ambrx Biopharma CEO to present at healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
conferences
News
Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory Affairs
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Stock AMAM logo
Ambrx Biopharma Inc.

Nasdaq:AMAM

AMAM Rankings

N/A Ranked by Market Cap
#3894 Ranked by Stock Gains
N/A Ranked by Dividends

AMAM Stock Data

1.77B
21.92M
2.1%
103.43%
1.83%
Biotechnology
Healthcare
Link
United States
La Jolla